# OnCo record mcn-associated-carcinoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/mcn-associated-carcinoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "mcn-associated-carcinoma" ;
  schema:name "Mucinous cystic neoplasm of the pancreas with associated invasive carcinoma (MCN-associated carcinoma)"@en ;
  schema:alternateName "Mucinous cystic neoplasm with associated invasive carcinoma (women, body and tail; 4 to 12 percent of resected MCNs)"@en, "Invasive MCN"@en, "Mucinous cystadenocarcinoma of the pancreas"@en, "MCN with invasive carcinoma"@en, "Malignant mucinous cystic neoplasm"@en ;
  schema:description "MCN-associated carcinoma is pancreatic cancer that has developed inside a mucinous cystic neoplasm, a thick-walled cyst with ovary-like tissue in its wall that occurs almost only in women, usually in the tail of the pancreas. Most such cysts are benign when removed; the minority with invasive cancer are larger, carry nodules and occur in older women, and about six in ten survive five years."@en ;
  schema:url <https://onco.cc/cancers/mcn-associated-carcinoma/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Pancreatic_mucinous_cystic_neoplasm> ;
  schema:citation <https://doi.org/10.1097/sla.0b013e31811f4449>, <https://doi.org/10.1097/mpa.0b013e3181f749d3>, <https://doi.org/10.1016/j.lanepe.2023.100673>, <https://doi.org/10.1111/his.13975>, <https://doi.org/10.1097/00000478-200101000-00003> ;
  onco:tag "gi", "pancreatic", "subtype-page" ;
  onco:related <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/ipmn-cystic-precursors/>, <https://onco.cc/cancers/ipmn-associated-carcinoma/>, <https://onco.cc/cancers/pancreatic-colloid-carcinoma/>, <https://onco.cc/cancers/pancreatic-undifferentiated-carcinoma-ogc/>, <https://onco.cc/cancers/mucinous-ovarian-cancer/> ;
  onco:technologies <https://onco.cc/technologies/robotic-surgery/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/histopathology-ihc/>, <https://onco.cc/technologies/mri/>, <https://onco.cc/technologies/endoscopic-ultrasound-systems/> ;
  onco:targets <https://onco.cc/targets/kras/> ;
  onco:drugs <https://onco.cc/drugs/folfirinox/>, <https://onco.cc/drugs/gemcitabine-nab-paclitaxel/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/>, <https://onco.cc/pathways/pancreatic-cancer-signalling/> ;
  onco:terms <https://onco.cc/terms/distal-pancreatectomy/>, <https://onco.cc/terms/pancreatic-cyst-high-risk-stigmata/>, <https://onco.cc/terms/resection-margins/>, <https://onco.cc/terms/tumour-grade/> ;
  onco:standardOfCare <https://onco.cc/terms/distal-pancreatectomy/>, <https://onco.cc/technologies/robotic-surgery/>, <https://onco.cc/drugs/folfirinox/>, <https://onco.cc/terms/neoadjuvant-adjuvant/>, <https://onco.cc/drugs/folfirinox/>, <https://onco.cc/drugs/gemcitabine-nab-paclitaxel/> .